-
公开(公告)号：US20080257631A1
公开(公告)日：2008-10-23
申请号：US11662685
申请日：2005-09-30
IPC分类号： B60K28/10
CPC分类号： B60K28/10 , A01D34/828 , B60Y2200/221 , B60Y2200/223 , B60Y2200/41
摘要： Control circuits for a riding lawn mower providing an override condition for selectively allowing the cutting blades of the lawn mower to operate when the vehicle is traveling in reverse. The circuits incorporate a multi-position ignition switch, an override switch, a vehicle reverse switch, a PTO switch and a park brake switch. In one aspect of the invention, the control circuits disable the engine when the vehicle is placed in reverse with the PTO engaged and without the override condition having been established. In another aspect of the invention, an electric PTO clutch is disabled when the vehicle is placed in reverse with the PTO engaged and without the override condition having been established. The override condition is terminated when the ignition switch is moved away from the override position, or when the operator activates the park brake switch.
摘要翻译： 用于骑马割草机的控制电路提供超驰条件，用于当车辆相反行驶时选择性地允许割草机的切割刀片操作。 电路包括多位置点火开关，超控开关，车辆倒车开关，PTO开关和驻车制动开关。 在本发明的一个方面，当车辆在PTO接合并且没有超驰条件已经建立的情况下，当车辆反向放置时，控制电路禁止发动机。 在本发明的另一方面，当PTO接合并且没有超驰条件被建立时，当车辆反向放置时，电动PTO离合器被禁用。 当点火开关离开超驰位置时，或当操作员启动驻车制动开关时，超驰条件终止。
-
公开(公告)号：US20080188485A1
公开(公告)日：2008-08-07
申请号：US12055900
申请日：2008-03-26
申请人： Bahige M. Baroudy , John W. Clader , Hubert B. Josien , Stuart W. McCombie , Brian A. McKittrick , Michael W. Miller , Bernard R. Neustadt , Anandan Palani , Elizabeth M. Smith , Ruo Steensma , Jayaram R. Tagat , Susan F. Vice , Mark A. Laughlin , Eric Gilbert , Marc A. Labroli
发明人： Bahige M. Baroudy , John W. Clader , Hubert B. Josien , Stuart W. McCombie , Brian A. McKittrick , Michael W. Miller , Bernard R. Neustadt , Anandan Palani , Elizabeth M. Smith , Ruo Steensma , Jayaram R. Tagat , Susan F. Vice , Mark A. Laughlin , Eric Gilbert , Marc A. Labroli
IPC分类号： A61K31/496 , A61P1/00 , A61P19/02
CPC分类号： C07D401/06 , A61K31/496 , A61K45/06 , C07D211/58 , C07D401/10 , C07D401/12 , C07D405/12 , C07D409/06 , C07D413/06 , A61K2300/00
摘要： The use of CCR5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R1 is hydrogen or alkyl; R2 is substituted phenyl, substituted heteroaryl, naphthyl fluorenyl, diphenylmethyl or optionally substituted phenyl- or heteroarylalkyl; R3 is hydrogen, alkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, or optionally substituted phenyl, phenylalkyl, naphthyl, naphthylalkyl, heteroaryl or heteroarylalkyl; R4, R5 and R7 are hydrogen or alkyl; R6 is hydrogen, alkyl or alkenyl; for the treatment of HIV, solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis is disclosed, as well as novel compounds, pharmaceutical compositions comprising them, and the combination of CCR5 antagonists of the invention in combination with antiviral agents useful in the treatment of HIV or agents useful in the treatment of inflammatory diseases.
摘要翻译： 使用下式的CCR5拮抗剂或其药学上可接受的盐，其中R是任选取代的苯基，吡啶基，噻吩基或萘基; R 1是氢或烷基; R 2是取代的苯基，取代的杂芳基，芴基，二苯甲基或任选取代的苯基或杂芳基烷基; R 3是氢，烷基，烷氧基烷基，环烷基，环烷基烷基或任选取代的苯基，苯基烷基，萘基，萘基烷基，杂芳基或杂芳基烷基; R 4，R 5和R 7是氢或烷基; R 6是氢，烷基或链烯基; 公开了用于治疗HIV，实体器官移植排斥，移植物抗宿主病，关节炎，类风湿性关节炎，炎症性肠病，特应性皮炎，牛皮癣，哮喘，过敏或多发性硬化的新型化合物，以及包含它们的药物组合物 ，以及本发明的CCR5拮抗剂与可用于治疗HIV的抗病毒剂或可用于治疗炎性疾病的药剂的组合。
-
公开(公告)号：US07307081B2
公开(公告)日：2007-12-11
申请号：US10738907
申请日：2003-12-17
申请人： Michael W. Miller , Jack D. Scott
发明人： Michael W. Miller , Jack D. Scott
IPC分类号： A61K31/497
CPC分类号： C07D401/14
摘要： The present invention provides a compound of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein the various moieties are as defined in the specification. The present invention also provides pharmaceutical compositions containing the compound of this invention, and methods of treatment using the compound of this invention. The invention also relates to the use of a combination of a compound of this invention and one or more antiviral or other agents useful in the treatment of Human Immunodeficiency Virus (HIV). The invention further relates to the use of a compound of this invention, alone or in combination with another agent, in the treatment of solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis.
摘要翻译： 本发明提供下式的化合物或其药学上可接受的盐或溶剂合物，其中各种部分如说明书中所定义。 本发明还提供含有本发明化合物的药物组合物和使用本发明化合物的治疗方法。 本发明还涉及本发明化合物与一种或多种可用于治疗人类免疫缺陷病毒（HIV）的抗病毒剂或其它药剂的组合的用途。 本发明还涉及本发明化合物单独或与另一种药剂组合用于治疗实体器官移植排斥，移植物抗宿主病，关节炎，类风湿性关节炎，炎症性肠病，特应性皮炎，牛皮癣 ，哮喘，过敏或多发性硬化。
-
公开(公告)号：US07008946B2
公开(公告)日：2006-03-07
申请号：US10970216
申请日：2004-10-21
申请人： Michael W. Miller
发明人： Michael W. Miller
IPC分类号： A61K31/496 , C07D401/14 , C07D409/14
CPC分类号： C07D401/14 , A61K31/18 , A61K31/506 , A61K45/06 , C07D403/06 , C07D409/14 , C07D417/14 , A61K2300/00
摘要： Compounds of the formula or a pharmaceutically acceptable salt or isomer thereof, wherein: Q, X and Z are CH or N; R, R4–R7 and R13 are H or alkyl; R1 is H, alkyl, fluoroalkyl, R9-arylalkyl, R9-heteroarylalkyl, alkyl-SO2—, cycloalkyl-SO2—, fluoroalkyl-SO2—, R9-aryl-SO2—, R9-heteroaryl-SO2—, N(R22)(R23)—SO2—, alkyl-C(O)—, cycloalkyl-C(O)—, fluoroalkyl-C(O)—, R9-aryl-C(O)—, NH-alkyl-C(O)— or R9-aryl-NH—C(O)—; R2 is H and R3 is H, alkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, R9-aryl, R9-arylalkyl, R9-heteroaryl, or R9-heteroarylalkyl, and when X and Z are each CH, R3 is alkoxy, R9-aryloxy, R9-heteroaryloxy, alkylC(O)O—, alkylaminoC(O)O—, alkylC(O)NR13—, alkylOC(O)NR13— or alkylaminoC(O)NR13—; or R2 and R3 together are ═O, ═NOR10, ═N—NR11R12 or ═CH-alkyl; R8 is substituted phenyl, substituted heteroaryl, naphthyl, fluorenyl, diphenymethyl, alpha-substituted benzyl or alpha-substituted heteroarylmethyl; R9–R12 are as defined; are disclosed for the treatment of HIV, solid organ transplant rejection, graft v. host disease, inflammatory diseases, atopic dermatitis, asthma, allergies or multiple sclerosis, as well as pharmaceutical compositions and combinations with antiviral or anti-inflammatory agents.
-
公开(公告)号：US06846570B2
公开(公告)日：2005-01-25
申请号：US10048782
申请日：2001-08-16
CPC分类号： A47J36/025 , A47J36/02 , B05D5/083 , B05D7/52 , Y10T428/31721 , Y10T428/31725 , Y10T428/31743 , Y10T428/3175
摘要： Multiple coat non-stick coating systems, as well as articles coated with such non-stick coating systems, are provided. The primer (22a) of the multiple coat system includes a fluoropolymer (14a) copolymer, such as a fluoropolymer terpolymer including tetrafluoroethylene, hexafluoropropylene, and vinylidene fluoride monomers, which fluoropolymer copolymers are referred to collectively as THV. The multiple coat system exhibits excellent substrate adhesion and release properties, and the primer exhibits excellent primer-substrate adhesion and primer-topcoat adhesion. The multiple coat system is additionally resistant to separation failure at the interface between the binder (12) and fluoropolymer components of the primer, exhibits excellent adhesion to smooth substrates (16), and may also include a high level of fillers to provide increased damage resistance without compromising the above benefits.
摘要翻译： 提供多层不粘涂层系统，以及涂有这种不粘涂层系统的物品。 多层涂布系统的底漆（22a）包括含氟聚合物（14a）共聚物，例如包含四氟乙烯，六氟丙烯和偏二氟乙烯单体的含氟聚合物三元共聚物，该含氟聚合物共聚物统称为THV。 多层涂层体系表现出优异的基材粘合性和剥离性，底漆表现出优异的底漆 - 底漆粘合性和底漆 - 面漆粘合性。 多层涂层系统另外抵抗粘合剂（12）和底漆的含氟聚合物组分之间的界面处的分离破坏，对光滑基材（16）表现出优异的粘附性，并且还可以包括高水平的填料以提供增强的耐损伤性 而不影响上述好处。
-
公开(公告)号：US06720325B2
公开(公告)日：2004-04-13
申请号：US10107940
申请日：2002-03-27
申请人： Michael W. Miller
发明人： Michael W. Miller
IPC分类号： A61K31496
CPC分类号： C07D401/14 , A61K31/18 , A61K31/506 , A61K45/06 , C07D403/06 , C07D409/14 , C07D417/14 , A61K2300/00
摘要： Compounds of the formula or a pharmaceutically acceptable salt or isomer thereof, wherein: Q, X and Z are CH or N; R, R4—R7 and R13 are H or alkyl; R1 is H, alkyl, fluoroalkyl, R9-arylalkyl, R9-heteroarylalkyl, alkyl-SO2—, cycloalkyl-SO2—, fluoroalkyl-SO2—, R9-aryl-SO2—, R9-heteroaryl-SO2—, N(R22)(R23)—SO2—, alkyl-C(O)—, cycloalkyl-C(O)—, fluoroalkyl-C(O)—, R9-aryl-C(O)—, NH-alkyl-C(O)— or R9-aryl-NH—C(O)—; R2 is H and R3 is H, alkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, R9-aryl, R9-arylalkyl, R9-heteroaryl, or R9-heteroarylalkyl, and when X and Z are each CH, R3 is alkoxy, R9-aryloxy, R9-heteroaryloxy, alkylC(O)O—, alkylaminoC(O)O—, alkylC(O)NR13—, alkylOC(O)NR13— or alkylaminoC(O)NR13—; or R2 and R3 together are ═O, ═NOR10, ═N—NR11R12 or ═CH-alkyl; R8 is substituted phenyl, substituted heteroaryl, naphthyl, fluorenyl, diphenymethyl, alpha-substituted benzyl or alpha-substituted heteroarylmethyl; R9—R12 are as defined; are disclosed for the treatment of HIV, solid organ transplant rejection, graft v. host disease, inflammatory diseases, atopic dermatitis, asthma, allergies or multiple sclerosis, as well as pharmaceutical compositions and combinations with antiviral or anti-inflammatory agents.
摘要翻译： 式的化合物或其药学上可接受的盐或异构体，其中：Q，X和Z是CH或N; R，R 4 -R 7和R 13是H或烷基; R 1是 H，烷基，氟烷基，R 9 - 芳基烷基，R 9 - 杂芳基烷基，烷基-SO 2 - ，环烷基-SO 2 - ，氟代烷基-SO 2 - ，R 9 - 芳基-SO 2 - ，R 9 - 杂芳基-SO 2 - ，N（R 22）（R 23）-SO 2 - ，烷基-C（O） - ，环烷基-C（O） - ，氟烷基-C（O） - ，R 9 芳基-C（O） - ，NH-烷基-C（O） - 或R 9 - 芳基-NH-C（O） - ; R 2是H，R 3是H，烷基， 烷氧基烷基，环烷基，环烷基烷基，R 9 - 芳基，R 9 - 芳烷基，R 9 - 杂芳基或R 9 - 杂芳基烷基，当X和Z各自为CH时，R 3为烷氧基 ，R 9 - 芳氧基，R 9 - 杂芳氧基，烷基C（O）O-，烷基氨基C（O）O-，烷基C（O）NR 13 - ，烷基OC（O）NR 13 - 或烷基氨基C （O）NR 13 - 或R 2和R 3一起为= O，= NOR 10，= N-NR 11 R 12或= CH-烷基; R 8 是取代的苯基，取代的杂芳基，萘基，芴基，二苯甲基，α-取代的苄基或α-取代的杂芳基甲基; R 9 -R 12如上所定义; 用于治疗HIV，实体器官移植排斥，移植物抗宿主病，炎性疾病，特应性皮炎，哮喘，过敏或多发性硬化，以及药物组合物和与抗病毒或抗炎剂的组合。
-
公开(公告)号：US06294554B1
公开(公告)日：2001-09-25
申请号：US09651652
申请日：2000-08-30
IPC分类号： A61K31445
CPC分类号： C07D401/14 , C07D211/58 , C07D405/14
摘要： Amide derivatives of 1,4 di-substituted piperidine compounds of the formula or a pharmaceutically acceptable salt, ester or solvate thereof, wherein Q and Q1 are each —CH═, or one of Q and Q1 is —CH═ and the other is —N═; X is —CH2— or Y and Z are —C(R5)═, or one of Y and Z is —C(R5)═ and the other is —N═; R1 is 1 to 3 substituents selected from H, halogen and alkoxy; R2 and R5 are 1 to 3 substituents selected from H, halogen, alkyl and alkoxy; and R3 and R4 are H or (C1-C6)alkyl are muscarinic antagonists useful for treating cognitive disorders such as Alzheimer's disease. Pharmaceutical compositions and methods of preparation are also disclosed.
摘要翻译： 式II的1,4-二取代哌啶化合物的酰胺衍生物或其药学上可接受的盐，酯或溶剂化物，其中Q和Q1各自为-CH =，或Q和Q1中的一个为-CH =，另一个为-N = ; X是-CH 2 - 或Y，Z是-C（R 5）=，或Y和Z之一是-C（R 5）=，另一个是-N =; R 1是1至3个选自H，卤素和 烷氧基; R2和R5是1至3个选自H，卤素，烷基和烷氧基的取代基; 和R 3和R 4是H或（C 1 -C 6）烷基是用于治疗认知障碍如阿尔茨海默氏病的毒蕈碱拮抗剂。 还公开了药物组合物和制备方法。
-
公开(公告)号：US5904599A
公开(公告)日：1999-05-18
申请号：US902300
申请日：1997-07-29
IPC分类号： H01R13/17
CPC分类号： H01R13/17
摘要： An electrical connector pin device includes an elongated body and a wire spring insert. The body has an external surface and defines an axial bore and a radial slot therein. The radial slot extends radially outwardly from the axial bore to the external surface, opening at the external surface. The wire spring insert is disposed within the axial bore and radial slot of the body. The wire spring insert is movable between non-compressed and compressed conditions. In the non-compressed condition, a portion of the wire spring insert extends above the external surface of the body, while in the compressed condition, the wire spring insert is deformed by an annular wall of a sleeve of an external electrical receptacle and pushed below the external surface of the body and thereby generates a spring force creating contact pressure diametrically opposed to the annular wall of the sleeve of the receptacle so as to releasably retain the body within the sleeve of the receptacle.
摘要翻译： 电连接器针装置包括细长主体和线弹簧插入件。 主体具有外表面并且在其中限定轴向孔和径向槽。 径向槽从轴向孔径向向外延伸到外表面，在外表面开口。 线弹簧插入件设置在主体的轴向孔和径向槽内。 线弹簧插件可在非压缩和压缩状态之间移动。 在非压缩状态下，线弹簧插入件的一部分在主体的外表面上方延伸，而在压缩状态下，线弹簧插件由外部电插座的套筒的环形壁变形并被推到下面 从而产生弹簧力，产生与容器的套筒的环形壁直径相对的接触压力，从而将本体可释放地保持在容器的套筒内。
-
-
-
-
-
-
-
搜索结果
68 条记录 (耗时 0.059 秒)
